Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (171-180 of 193) with videos related to

Pageof 20
Sort By:
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' projectFrancesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Transplantation and Cellular Therapy|February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsChenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Cancers|May 14, 2025
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Daniela Cilloni, Marta Riva, et al.
Blood|January 9, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosisIlaria Crespiatico, Mattia Zaghi, Cristina Mastini, et al.
Pageof 20

Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' projectFrancesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Transplantation and Cellular Therapy|February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsChenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Cancers|May 14, 2025
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Daniela Cilloni, Marta Riva, et al.
Blood|January 9, 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosisIlaria Crespiatico, Mattia Zaghi, Cristina Mastini, et al.
Pageof 20